Veracyte, Inc.

VCYT Healthcare Diagnostics & Research

Veracyte, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $517.1 million, up 16.0% from fiscal 2024. In the quarter to June 2026, revenue grew 15.5%, EPS grew 3,300.0% and free cash flow grew 33.0%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.

43.12 1.27 −2.86%
Market cap
$3.6B
P/E
29.9×
Fwd P/E
45.1×
Dividend yield
—
F-score
8/9
Altman Z
21.08
Beneish M
−2.66
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

88.03 50.12 29.02 40.78
P/S ratio
5.46 6.40 4.73 8.36
P/FCF ratio
27.52 26.13 16.49 28.30
P/Operating CF
60.38 62.92 72.75 102.49
P/B ratio
2.15 2.53 1.91 3.38
Price to Tangible BV
6.79 7.30 5.21 8.72
EV/Sales
4.72 5.60 3.92 7.50
EV/EBITDA
52.96 38.17 22.14 34.00
EV/Operating CF
21.60 21.26 12.79 23.62
EV/FCF
23.81 22.88 13.68 25.39
Quick Ratio
5.74 7.63 8.72 8.60
Current Ratio
6.23 8.15 9.31 9.16
Net Debt/EBITDA
(13.31) (9.87) (15.99) (17.91)
Debt/Assets
0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00
Asset Turnover
0.37 0.38 0.39 0.40
Operating CF/Net income
2.34 1.28 1.23 1.80
Capex/Depreciation
(0.61) (0.81) (0.61) (0.69)
Research and Development Expense of Revenue
12.12% 14.82% 19.49% 19.59%
Selling, General and Administrative Expense of Revenue
39.23% 30.79% 36.55% 37.06%
Intangible Assets out of Total Assets
0.63 0.61 0.59 0.57
Share Based Compensation of Revenue
8.16% 7.75% 9.18% 9.37%
Graham Net Nets
0.13 0.12 0.17 0.10
Graham Number
11.84 17.75 20.55 23.72
Earnings Yield
1.14% 2.00% 3.45% 2.45%
Free Cash Flow Yield
3.63% 3.83% 6.06% 3.53%
Revenue per Share
1.68 1.79 1.75 1.88
Operating CF per Share
0.57 0.67 0.44 0.57
Capex per Share
(0.04) (0.05) (0.04) (0.04)
Free Cash Flow per Share
0.53 0.62 0.41 0.54
Cash per Share
4.65 5.25 5.52 6.07
Shareholders Equity per Share
15.98 16.66 16.90 17.36
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
15.98 16.66 16.90 17.36
Free Cash Flow
41.97 48.80 32.25 42.97
Working Capital
377.07 428.44 466.06 512.04
Capital Expenditures
(2.79) (3.78) (2.96) (2.86)
Net Current Asset Value
339.10 391.93 430.18 476.81
EV/EBIT
94.46 50.15 27.41 39.84
Capex to Sales
0.02 0.03 0.02 0.02
Price to Operating Income
109.17 57.26 33.05 44.41
Other line items
Average Receivables
48.32 45.59 51.95 52.50
Average Payables
7.59 6.61 11.31 9.74
Average Inventory
20.35 21.15 22.84 23.84
Average Assets
1,321.40 1,353.03 1,375.91 1,415.24
Average Common Equity
1,216.85 1,242.77 1,269.67 1,304.73

Fold the line items

Columns are period end dates